Time-course of myelination and atrophy on cerebral imaging in 35 patients with PLP1-related disorders

Developmental Medicine and Child Neurology

Volumn 58, Issue 7, 2016, Pages 706-713

  Sarret, Catherine ^a,b   Lemaire, Jean Jacques ^a,b   Tonduti, Davide ^c,d   Sontheimer, Anna ^a   Coste, Jerome ^a   Pereira, Bruno ^a,b   Feschet, Fabien ^a   Roche, Basile ^a   Boespflug Tanguy, Odile ^c,e  

^a UNIVERSITÉ CLERMONT AUVERGNE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d DEPARTMENT OF NEUROSURGERY   (Italy)

^e HÔPITAL ROBERT DEBRÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BRAIN ATROPHY; BRAIN SIZE; CAPSULA INTERNA; CEREBELLUM; CEREBELLUM ATROPHY; CHILD; CLINICAL ARTICLE; CORPUS CALLOSUM; DEMYELINATING DISEASE; DEMYELINATION; DISEASE SEVERITY; GENE; GENE MUTATION; GRAY MATTER; HUMAN; IMAGE PROCESSING; INFANT; MALE; MOTOR DEVELOPMENT; MYELINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIA; PATHOPHYSIOLOGY; PELIZAEUS MERZBACHER DISEASE; PLP1 RELATED DISORDER; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEOLIPID PROTEIN 1 GENE; SCHOOL CHILD; SPASTIC PARAPLEGIA; SPASTIC PARAPLEGIA TYPE 2; SUBARACHNOID SPACE; WHITE MATTER; YOUNG ADULT;

EID: 84975121897     PISSN: 00121622     EISSN: 14698749     Source Type: Journal    
DOI: 10.1111/dmcn.13025     Document Type: Article

References (22)

1. Cailloux F, Gauthier-Barichard F, Mimault C, et al. Genotype-phenotype correlation in inherited brain myelination defects due to proteolipid protein gene mutations. Clinical European Network on Brain Dysmyelinating Disease. Eur J Hum Genet 2000; 8: 837–45.
2. Steenweg ME, Vanderver A, Blaser S, et al. Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain 2010; 133: 2971–82.
3. van der Knaap MS, Valk J. Myelination and retarded myelination. In: van der Knaap MS, Valk J, editors. Magnetic Resonance of Myelin, Myelination, and Myelin Disorders. Berlin: Springer-Verlag, 1995: 31–52.
4. Nezu A, Kimura S, Takeshita S, et al. An MRI and MRS study of Pelizaeus-Merzbacher disease. Pediatr Neurol 1998; 18: 334–37.
5. Takanashi J, Sugita K, Tanabe Y, et al. MR-revealed myelination in the cerebral corticospinal tract as a marker for Pelizaeus-Merzbacher's disease with proteolipid protein gene duplication. Am J Neuroradiol 1999; 20: 1822–28.
6. Plecko B, Stöckler-Ipsiroglu S, Gruber S, et al. Degree of hypomyelination and magnetic resonance spectroscopy findings in patients with Pelizaeus-Merzbacher phenotype. Neuropediatrics 2003; 34: 127–36.
7. Gupta N, Henry RG, Strober J, et al. Neural stem cell engraftment and myelination in the human brain. Sci Transl Med 2012; 4: 155ra137.
8. Boespflug-Tanguy O, Labauge P, Fogli A, Vaurs-Barriere C. Genes involved in leukodystrophies: a glance at glial functions. Curr Neurol Neurosci Rep 2008; 8: 217–29.
9. Laukka JJ, Stanley JA, Garbern JY, et al. Neuroradiologic correlates of clinical disability and progression in the X-linked leukodystrophy Pelizaeus-Merzbacher disease. J Neurol Sci 2013; 335: 75–81.
10. Inoue K. PLP1-related inherited dysmyelinating disorders: Pelizaeus-Merzbacher disease and spastic paraplegia type 2. Neurogenetics 2005; 6: 1–16.
11. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990; 1: 43–46.
12. Feise RJ. Do multiple outcome measures require p-value adjustment? BMC Med Res Methodol 2002; 2: 8.
13. Wang PJ, Young C, Liu HM, et al. Neurophysiologic studies and MRI in Pelizaeus-Merzbacher disease: comparison of classic and connatal forms. Pediatr Neurol 1995; 12: 47–53.
14. Biancheri R, Grossi S, Regis S, et al. Further genotype-phenotype correlation emerging from two families with PLP1 exon 4 skipping. Clin Genet 2014; 85: 267–72.
15. Sima AA, Pierson CR, Woltjer RL, et al. Neuronal loss in Pelizaeus-Merzbacher disease differs in various mutations of the proteolipid protein 1. Acta Neuropathol 2009; 118: 531–39.
16. Garbern JY, Yool DA, Moore GJ, et al. Patients lacking the major CNS myelin protein, proteolipid protein 1, develop length-dependent axonal degeneration in the absence of demyelination and inflammation. Brain 2002; 125: 551–61.
17. Miller MJ, Haxhiu MA, Georgiadis P, et al. Proteolipid protein gene mutation induces altered ventilatory response to hypoxia in the myelin-deficient rat. J Neurosci 2003; 23: 2265–73.
18. McLaughlin M, Barrie JA, Karim S, et al. Processing of PLP in a model of Pelizaeus-Merzbacher disease/SPG2 due to the rumpshaker mutation. Glia 2006; 53: 715–22.
19. Anderson TJ, Schneider A, Barrie JA, et al. Late-onset neurodegeneration in mice with increased dosage of the proteolipid protein gene. J Comp Neurol 1998; 394: 506–19.
20. Bongarzone ER, Campagnoni CW, Kampf K, et al. Identification of a new exon in the myelin proteolipid protein gene encoding novel protein isoforms that are restricted to the somata of oligodendrocytes and neurons. J Neurosci 1999; 19: 8349–57.
21. Sarret C, Combes P, Micheau P, et al. Novel neuronal proteolipid protein isoforms encoded by the human myelin proteolipid protein 1 gene. Neuroscience 2010; 166: 522–38.
22. Kosar MI, Karacan K, Otag I, et al. Determination of cerebellar volume in children and adolescents with magnetic resonance images. Folia Morphol 2012; 71: 65–70.